Merus hails 'unprecedented' survival on solid tumor bispecific, sparking stock jump
Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair analysts' belief the candidate has a “best-in-disease profile.”
Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair analysts' belief the candidate has a “best-in-disease profile.”
